Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer

Conference Correspondent  - SABCS

Although a lower percentage of patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) develop brain metastases when compared with patients with triple-negative and HER2-positive MBC, no systemic agents are approved for the treatment of brain metastases in patients with HR-positive breast cancer, and this remains an unmet medical need. Standard local treatment options include surgery, stereotactic radiosurgery, and/or whole-brain radiation therapy.

Abemaciclib, an oral selective CDK4/6 inhibitor administered on a continuous dosing schedule, has demonstrated clinical activity and an acceptable safety profile in heavily pretreated patients with HR-positive MBC.1 Preclinically, abemaciclib crosses the blood‒brain barrier, which is further supported clinically by detectable levels of abemaciclib similar to plasma levels in resected brain metastases in a subset of patients with HR-positive/HER2-negative MBC, as previously reported.2 These data provided a rationale for evaluating abemaciclib in patients with brain metastases.

The current study was an open-label, phase 2, Simon’s 2-stage trial evaluating the safety and efficacy of abemaciclib up to 200 mg twice daily in 4 cohorts of patients with brain metastases secondary to HR-positive MBC, non–small-cell lung cancer, or melanoma.3 Regarding HR-positive MBC, one cohort included HR-positive/HER2-negative patients, and another included HR-positive/HER2-positive patients. All HR-positive MBC patients enrolled to 1 of these 2 cohorts were required to have ≥1 measurable brain lesions. The primary objective was objective intracranial response rate as defined by Response Assessment in Neuro-Oncology Brain Metastases response criteria. Stage 1 was to enroll 23 evaluable patients per study part; if <2 responded, accrual was to be stopped. If ≥2 responded to abemaciclib, 33 additional evaluable patients were to be enrolled to stage 2. In stage 2, a response in 6 patients is required to warrant further investigation of abemaciclib in this patient population.

For stage 1 efficacy, in patients with HR-positive/HER2-positive MBC, futility was met. However, for HR-positive/HER2-negative patients, 2 confirmed, durable partial responses were observed, and enrollment to stage 2 is ongoing.

Previously, this study provided evidence that abemaciclib penetrates brain metastases in patients with HR-positive/HER2-negative MBC. The current results provided sufficient evidence of antitumor activity on brain metastases in patients with HR-positive/HER2-negative MBC, with an overall response rate of 8.7% and clinical benefit rate of 17.4%, to merit further exploration, but not for patients with HR-positive/HER2-positive disease. Safety and tolerability results were similar to those previously reported for abemaciclib, with the majority of adverse events being gastrointestinal (82.6% of patients with HR-positive/HER2-negative MBC and 65.2% of patients with HR-positive/HER2-positive MBC experienced diarrhea).

References
1. Dickler MN, et al. Clin Cancer Res. 2017;23:5218-5224.
2. Torres-Guzmán R, et al. Oncotarget. 2017;8:69493-69507.
3. Bachelot T, et al. SABCS 2017. Abstract P1-17-03.

Related Items
Questions About Treating Patients Using a CDK4/6 Inhibitor
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
The Use of Chemotherapy in the Metastatic Setting
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
The Mechanism of Action of CDK4/6 Inhibitors
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
New Oral SERD Elacestrant Shows Efficacy in Breast Cancer Harboring ESR1 Mutations
Conference Correspondent  published on December 10, 2017 in SABCS
CDK6 Could Be a Key Factor for Efficacy of CDK4/6 Inhibitors and the Hormone Sensitivity Following Acquired Resistance
Conference Correspondent  published on December 10, 2017 in SABCS
Therapeutic Targeting of CDK4/6 Inhibitor–Resistant Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
Loss of Mismatch Repair Predicts Resistance to Endocrine Therapy and Sensitivity to CDK4/6 Inhibitors in ER-Positive Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
Xentuzumab and Abemaciclib plus Endocrine Therapy in Locally Advanced/Metastatic Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  published on December 9, 2017 in Breast Cancer, Video, SABCS
Last modified: April 27, 2020